A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy

References

• European Association for the Study of the LiverEASL clinical practice guidelines: management of chronic hepatitis BJ Hepatol200950222724219054588
   PubMed Web of Science ®Google Scholar
• DienstagJLHepatitis B virus infectionN Engl J Med2008359141486150018832247
   PubMed Web of Science ®Google Scholar
• CareyIHarrisonPMMonotherapy versus combination therapy for the treatment of chronic hepatitis BExpert Opin Investig Drugs2009181116551666
   PubMed Web of Science ®Google Scholar
• ChangTTGishRGde ManRBEHoLD AI463022 Study GroupA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006354101001101016525137
   PubMed Web of Science ®Google Scholar
• MarcellinPHeathcoteEJButiMTenofovir disoproxil fumarate versus adefovir dipivoxil for chronic hepatitis BN Engl J Med2008359232442245519052126
   PubMed Web of Science ®Google Scholar
• WooGTomlinsonGNishikawaYTenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analysesGastroenterology2010 [Epub ahead of print]
   Google Scholar
• GianniniEGTorreFBassoMLigurian Hepatitis B Virus Study Group. A significant proportion of patients with chronic hepatitis B who are candidates for antiviral treatment are untreated: a region-wide survey in ItalyJ Clin Gastroenterol200943101001100719318981
   PubMed Web of Science ®Google Scholar
• GaetaGBStornaiuoloGPreconeDFEpidemiological and clinical burden of chronic hepatitis B virus/hepatitis C virus infection. A multicenter Italian studyJ Hepatol20033961036104114642623
   PubMed Web of Science ®Google Scholar
• IdrisBIBrosaMRichardusJHEstimating the future health burden of chronic hepatitis B and the impact of therapy in SpainEur J Gastroenterol Hepatol200820432032618334876
   PubMed Web of Science ®Google Scholar
• HeathcoteJEGaneEJde ManATwo year tenofovir disoproxil fumarate (TDF) treatment and adenofovir dipivoxil (ADV) switch data in HbeAg-positive patients with chronic hepatitis B (Study 103), preliminary analysis [Abstract]Hepatology200848Suppl 4309A
   Web of Science ®Google Scholar
• HeathcoteJEGaneEJde ManAThree years of tenofovir disoproxil (TDF) treatment in HbeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103), preliminary analysis [Abstract]Hepatology200950Suppl 4533A
   Web of Science ®Google Scholar
• ChangTTGishRGde ManRA comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis BN Engl J Med2006354101001101016525137
   PubMed Web of Science ®Google Scholar
• LaiCLYuenMFChronic hepatitis B: new goals, new treatmentN Engl J Med2008359232488249119052131
   PubMed Web of Science ®Google Scholar
• MarcellinPChangTTLimSGAdefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BN Engl J Med2003348980881612606735
   PubMed Web of Science ®Google Scholar
• LaiCLGaneELiawYFTelbivudine versus lamivudine in patients with chronic hepatitis BN Engl J Med2007357252576258818094378
   PubMed Web of Science ®Google Scholar
• LaiCLGaneEHsuCWTwo-year results from the globe trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LDT) vs lamivudine [Abstract]Hepatology200644Suppl 1222A
   Google Scholar
• MarcellinPButiMKrastevZTwo year tenofovir disoproxil fumarate (TDF) treatment and adenofovir dipivoxil (ADV) switch data in HbeAg-negative patients with chronic hepatitis B (Study 102), preliminary analysis [Abstract]Hepatology200848Suppl 4370A
   Web of Science ®Google Scholar
• MarcellinPButiMKrastevZThree years of tenofovir disoproxil (TDF) treatment in HbeAg-positive patients (HBeAg+) with chronic hepatitis B (Study 103), preliminary analysis [Abstract]Hepatology200950Suppl 4532A
   Web of Science ®Google Scholar
• Di MarcoVMarzanoALamperticoPItalian Association for the Study of the Liver (AISF) Lamivudine Study Group, Italy. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudineHepatology200440488389115382125
   PubMed Web of Science ®Google Scholar
• HadziyannisSJTassopoulosNCHeathcoteEJAdefovir Dipivoxil 438 Study Group. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 yearsGastroenterology200613161743175117087951
   PubMed Web of Science ®Google Scholar
• SenturkHLurieYGadanoAETV re-treatment of nucleoside-naive HBeAg(–) [Abstract]J Hepatol200746Suppl 1S197
   Web of Science ®Google Scholar
• ShouvalDLaiCLChangTTThree years of entecavir (ETV) re-treatment of HBeAg(–) ETV patients who previously discontinued ETV treatment: results from study ETV-901Hepatology200848Suppl 4722A
   Web of Science ®Google Scholar
• LaiCLShouvalDLokASBEHoLD AI463027 Study GroupEntecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis BN Engl J Med20063541010111020Erratum in: N Engl J Med. 2006;354(17):186316525138
   PubMed Web of Science ®Google Scholar
• ShouvalDAkarcaUSHatzisGContinued virologic and biochemical improvement through 96 weeks of entecavir treatment in HBeAg(–) chronic hepatitis B patients (study ETV-027)J Hepatol200644Suppl 2S21S22
   Web of Science ®Google Scholar
• WangYThongsawatSGaneEJEfficacy and safety outcomes after 4 years of telbivudine treatment in patients with chronic hepatitis B (CHB)Hepatology200950Suppl 4533A
   Google Scholar
• Snow-LampartAChappellBJCurtisMHBeAg+ and HBeAg–hepatitis B patients treated with tenofovir df showed no relationship between virologic breakthrough and emergence of genotypic changes in HBV polymeraseHepatology200950Suppl 4523A
   Web of Science ®Google Scholar
• LokASLaiCLLeungNLong-term safety of lamivudine treatment in patients with chronic hepatitis BGastroenterology200312561714172214724824
   PubMed Web of Science ®Google Scholar
• MarcellinPChangTTLimSGLong-term efficacy and safety of adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis BHepatology200848375075818752330
   PubMed Web of Science ®Google Scholar
• TenneyDJRoseREBaldickCJLong-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years of therapyHepatology20094951503151419280622
   PubMed Web of Science ®Google Scholar
• LiawYFGaneELeungNGLOBE Study Group. 2-year GLOBE trial results: telbivudine is superior to lamivudine in patients with chronic hepatitis BGastroenterology2009136248649519027013
   PubMed Web of Science ®Google Scholar
• FontanaRJHepatitis B: a “GLOBAL” health challengeGastroenterology2009136238939219109963
   PubMed Web of Science ®Google Scholar
• BusterEHFlinkHJCakalogluYSustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2bGastroenterology2008135245946718585385
   PubMed Web of Science ®Google Scholar
• JanssenHLvan ZonneveldMSenturkHHBV 99-01 Study Group; Rotterdam Foundation for Liver Research. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trialLancet2005365945412312915639293
   PubMed Web of Science ®Google Scholar
• MarcellinPLauGKBoninoFPeginterferon Alfa-2a HBeAg-Negative Chronic Hepatitis B Study Group. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis BN Engl J Med2004351121206121715371578
   PubMed Web of Science ®Google Scholar
• MarcellinPBoninoFLauGKPeginterferon alfa-2a in HBeAg-negative Chronic Hepatitis B Study Group. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2aGastroenterology2009136721692179e1e419303414
   PubMed Web of Science ®Google Scholar
• LauGKCurrent treatments for patients with HBeAg-positive chronic hepatitis B virus infection: a comparison focusing on HBeAg seroconversionLiver Int201030451252020102511
   PubMed Web of Science ®Google Scholar
• MarcellinPChangTTLimSLong term efficacy and safety of adefovir dipivoxil (ADV) 10 mg in HBeAg+ chronic hepatitis B (CHB) patients increasing serologic, virologic and biochemical response over timeHepatology200440(1) Suppl 4655A
   Web of Science ®Google Scholar
• LeungNPengCYSollanoJEntecavir (ETV) results in higher HBV DNA reduction versus adefovir (ADV) in antiviralnaive HBeAg+ adults with high HBVDNA: Week 96 results (E.A.R.L.Y. study)J Hepatol200848S373S374
   Web of Science ®Google Scholar
• YaoGChenCWLuWLVirologic, serologic, and biochemical outcomes through 2 years of treatment with entecavir and lamivudine in nucleoside-naive Chinese patients with chronic hepatitis B: a randomized, multicenter studyHepatol Int2008248649319669324
   PubMed Web of Science ®Google Scholar
• HanSChangT-TChaoYCFour-year entecavir treatment in nucleosidenaïve HBeAg(+) patients: results from studies ETV-022 And -901Hepatology200746(4) Suppl 1654A
   Google Scholar
• HouJYinYKXuDTelbivudine versus lamivudine in Chinese patients with chronic hepatitis B: results at 1 year of a randomized, double-blind trialHepatology20084744745418080339
   PubMed Web of Science ®Google Scholar
• PiratvisuthTLauGChaoYCSustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis BHepatol Int20082110211019669285
   PubMed Web of Science ®Google Scholar
• DrummondMFSchulpherMJTorranceGWMethods for the Economic Evaluation of Health Care Programmes3rd edOxfordOxford University Press2005
   Google Scholar
• EnriquezADCampbellMSReddyKRCost-effectiveness of suppressing hepatitis B virus DNA in immune tolerant patients to prevent hepatocellular carcinoma and cirrhosisAliment Pharmacol Ther200726338339117635373
   PubMed Web of Science ®Google Scholar
• SullivanSDCraxiAAlbertiARapporto costo efficacia della terapia peginterferone alfa-2a+ ribavirina in confronto a interferone alfa-2b+ ribavirina in pazienti affetti da epatite cronica di tipo C precedentemente non trattatiPharmacoEconomics20046105114
   Google Scholar
• KanwalFGralnekIMMartinPTreatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysisAnn Intern Med20051421082183115897532
   PubMed Web of Science ®Google Scholar
• ChapmanRHStonePWSandbergEAA comprehensive league table of cost-utility ratios and a sub-table of “panel-worthy” studiesMed Decis Making200020445146711059478
   PubMed Web of Science ®Google Scholar
• Health MinistryNational Tariff Nomenclature. Nomenclatore delle Prestazioni di assistenza specialistica ambulatoriale Ministero della Salute2010
   Google Scholar
• Conferenza delle Regioni e delle Province autonome 1O/014/CR10a/C7. DRG 206, Tariffa Unica Convenzionale (TUC) per le prestazioni di assistenza ospedaliera, regole e tariffe valide per l’anno 2009secondo CMS-DRG Versione 24. DRG 206; DRG 202; DRG 199; DRG 480; Roma2010
   Google Scholar
• TumiattiCBezzonCGuastiFFranchinM Il costo del trapianto d’organo: risultati di uno studio condotto presso l’Azienda Ospedaliera di Padova. Azienda Ospedaliera di Padova. 1999:39. valori attualizzati al 2009
   Google Scholar
• Gazzetta Ufficiale n 216 of 14/09/1996: DM 22/07/1996; 89.7: visita specialistica, prima visita. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio sanitario nazionale e relative tariffe
   Google Scholar
• Gazzetta Ufficiale n 216 of 14/09/1996: DM 22/07/1996;90.16.3: creatinina, 90.24.3 fosfato organico. Prestazioni di assistenza specialistica ambulatoriale erogabili nell’ambito del Servizio sanitario nazionale e relative tariffe
   Google Scholar
• The National Institute for Health and Clinical Excellence Social value judgements: principles for the development of NICE guidance. Second ed. 2008. http://www.nice.org.uk/media/C18/30/SVJ2PUBLICATION2008.pdf. Accessed July 14, 2010
   Google Scholar
• ButiMBrosaMCasadoMAModeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis BJ Hepatol200951464064619576651
   PubMed Web of Science ®Google Scholar
• DakinHBentleyADusheikoGCost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis BValue Health932010 [Epub ahead of print]
   Web of Science ®Google Scholar
• Associazione Italiana di Economia Sanitaria (AIES)Proposta di linee guida per la valutazione economica degli interventi sanitariPharmacoEconomics – Italian Research Articles2009118393
   Google Scholar
• LucioniCRavasioRCome valutare i risultati di uno studio farmacoeconomico?PharmacoEconomics – Italian Research Articles20043121130
   Google Scholar
• MessoriASantarlasciBTrippoliSVaianiMControvalore economico del farmaco e beneficio clinico: Stato dell’arte della metodologia e applicazione di un algoritmo farmacoeconomicoPharmacoEconomics – Italian Research Articles200355367
   Google Scholar